PT-2385 (30 or 100 mg/kg; oral gavage; twice daily) result in a rapid, dose-dependent tumor regression[3].
PT-2385 (PT2385) inhibits expression of HIF-2α regulated genes in a dose dependent manner in vivo. Tumor is regressed with PT-2385 (3 and 10 mg/kg, p.o., b.i.d. dose) in 786-O xenograft. PT-2385 (1,3 and 10 mg/kg) also inhibits tumor-derived VEGFA protein levels. PT-2385 (10 mg/kg) treatment reduces proliferation (Ki67) and angiogenesis (CD-31)[1].
| Animal Model: | SCID/beige mice with the 786-O and A498 RCC cell lines[3] |
| Dosage: | 30 or 100 mg/kg |
| Administration: | Oral gavage; twice daily |
| Result: | Resulted in a rapid, dose-dependent tumor regression.
|
